Legal, Regulatory & Compliance

Canada-based legal and consulting practice advising regulated-industry clients on psychedelic access, controlled-substance pathways, constitutional/regulatory issues, and policy-facing market development.

Canadian business law firm with published advisory work on legal and regulatory frameworks for psychedelics companies, including public-market and disclosure implications under Canadian law.

Law firm providing psychedelic-sector legal counsel across DEA/FDA pathway navigation, transactional support, and healthcare-compliance risk management for clinics, facilitators, and research organizations.

Regulatory and scientific consulting provider for psychedelic businesses and research teams, with operational compliance support for licensing, security, SOP design, and controlled-substance workflows.

Psychedelic and psilocybin-focused legal practice supporting operators and organizations with regulatory navigation, compliance strategy, and legal risk mitigation in emerging plant-medicine markets.

International regulatory affairs consultancy (UK/EU/US footprint) supporting life-science organizations across development to post-licensing, including dedicated analysis of psychedelic-drug regulatory pathways.

Brazil-based law firm with a leading IP and life-sciences practice, contributing legal and regulatory analysis on psychedelic medicines in Brazil and advising on IP-protection strategy in regulated sectors.

US pharmacovigilance and drug-safety specialist providing adverse-event reporting, medical monitoring, and compliance operations for biotech and pharmaceutical sponsors, including psychedelic clinical programs.

Toronto-based boutique law firm operating a dedicated psychedelic law practice, advising individuals and organizations on regulatory compliance, governance, contracts, and legal risk in Canada’s psychedelic sector.

National law firm with a dedicated psychedelics and emerging therapies legal practice supporting organizations operating in complex U.S. therapeutic, regulatory, and commercialization pathways.

Canadian law firm with a dedicated cannabis-and-psychedelics regulatory practice advising on Section 56 pathways, Special Access Program matters, licensing compliance, and controlled-substance legal strategy.

UK law firm with a dedicated psychoactive medicines practice providing regulatory, commercial, and IP counsel for psychedelic and cannabis organizations across research, clinic, and supply-chain contexts.

Nonprofit psychedelic prior-art and patent-analysis organization that supports patent quality, prior-art discovery, and intellectual-property transparency for innovators, examiners, and the public.

Toronto law firm focused on psychedelics and controlled-substance legal operations, supporting licensing strategy, Health Canada interactions, audit/inspection readiness, and compliance architecture across research-to-commercial pathways.

Psychedelic-focused law firm advising clinics, researchers, nonprofit organizations, and religious groups on controlled-substance licensing, compliance strategy, and policy-facing legal frameworks.

Law firm focused on cannabis and psychedelics law, with advisory work spanning FDA/DEA pathways, controlled-substance compliance, and policy implementation in emerging psychedelic regulatory programs.